Peptuvia

AOD-9604 vs Semaglutide

These two are popular fat-metabolism research compounds with nothing mechanistically in common. AOD-9604 is a growth-hormone fragment; semaglutide is a GLP-1 agonist. The comparison is really about two very different routes to the same research area.

AOD-9604Semaglutide
Compound classGrowth-hormone fragment (176-191)GLP-1 receptor agonist
Primary targetLipolytic GH fragmentGLP-1 receptor
CategoryGLP-1 & MetabolicGLP-1 & Metabolic
AdministrationDaily subcutaneousWeekly subcutaneous
Research focusFat metabolism without systemic GH effectsAppetite signaling & glycemic control

Key differences

  • Mechanism: AOD-9604 is a modified GH fragment (176-191) studied for lipolysis; semaglutide is a GLP-1 receptor agonist acting on appetite and glycemic signaling.
  • Appetite: semaglutide directly influences appetite signaling; AOD-9604 is studied for fat metabolism without the broad GH or appetite effects.
  • Dosing cadence: AOD-9604 research is typically daily; semaglutide is weekly.
  • Effect profile: semaglutide has large, well-documented metabolic effects; AOD-9604 is a milder, more targeted lipolytic research tool.

Which is right for your research?

Semaglutide is the heavyweight appetite/glycemic compound; AOD-9604 is the lightweight GH-fragment option for lipolysis-focused research without incretin activity.

Frequently asked questions

Do AOD-9604 and semaglutide work the same way?

No. AOD-9604 is a growth-hormone fragment studied for fat metabolism, while semaglutide is a GLP-1 agonist that acts on appetite and glycemic pathways.

How often is each dosed in research?

AOD-9604 is typically dosed daily; semaglutide is dosed weekly.

Which has the larger effect?

Semaglutide has the larger, better-documented metabolic effect; AOD-9604 is a milder, more targeted lipolytic compound.

For Research Use Only. All products are sold as research chemicals for in-vitro laboratory study. Not for human consumption, medical, veterinary, or household use.